Product Description
Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. (Sourced from: https://www.nejm.org/doi/full/10.1056/nejmoa1310422)
Mechanisms of Action: Cell Wall Inhibitor
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Czech | Estonia | European Medicines Agency | Finland | Germany | Greece | Hungary | Iceland | Ireland | Italy | Jordan | Latvia | Lithuania | Poland | Portugal | Saudi Arabia | Slovakia | Spain | Sweden | Switzerland | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Melinta
Company Location: MORRISTOWN NJ 07963
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Bulgaria, Greece, Latvia, Lithuania, Poland, Portugal, Romania, Spain, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Other
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05599295 |
ML-ORI-201 | P2 |
Recruiting |
Other |
2025-12-01 |
2% |
2025-09-24 |
|
2024-516385-10-00 |
ML-ORI-201 | P2 |
Not yet recruiting |
Unknown |
2025-06-30 |
2% |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/31/2025 |
News Article |
CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025 |
|
10/23/2025 |
News Article |
CorMedix Inc. Receives Innovative Technology Designation From Vizient for DefenCath |
|
09/08/2025 |
News Article |
CorMedix Announces Strategic Minority Investment in Talphera |
|
09/05/2025 |
News Article |
Deerfield Management Announces Sale of Melinta Therapeutics |